TOWARD: A Scalable Metabolic Health Intervention for Weight Loss and Medication Deprescription

A groundbreaking study published in Frontiers in Nutrition 📑 shows that a therapeutic carbohydrate reduction (TCR)-based telemedicine program, TOWARD, led to robust 1-year weight loss & major cost savings 💰—without relying on expensive GLP-1 medications!

🔥 Key Findings:

✅ -15.5% weight loss on average (comparable to GLP-1 meds!)

✅ 96 medications deprescribed (including diabetes & hypertension meds)

✅ $1,700 annual savings per patient compared to GLP-1 therapy ($13,000/year)

✅ Sustained weight loss even after stopping GLP-1 meds

💡 TOWARD proves that lifestyle-based metabolic health interventions can rival drug-based treatments—offering a scalable, cost-effective alternative for obesity & type 2 diabetes.

🔗 Read the full study:

Buchanan, L., Calkins, M., Kalayjian, T., Norwitz, N. G., Teicholz, N., Unwin, D., & Soto-Mota, A. (2025). TOWARD, a metabolic health intervention, demonstrates robust 1-year weight loss and cost-savings through deprescription. Frontiers in Nutrition, 12, 1548609. https://doi.org/10.3389/fnut.2025.1548609

#MetabolicHealth #WeightLoss #Diabetes #LowCarb #TCR #HealthTech #GLP1 #CostSavings #NutritionScience